Ozempic and Wegovy, the blockbuster weight loss drugs that have transformed the lives of millions, are going generic in India because the patent on their core active ingredient, semaglutide, has expired. This has triggered a massive wave of low-priced generic alternatives from over 40 domestic pharmaceutical companies, which is expected to slash the drug’s monthly cost from ₹8,000 to ₹18,000 per month to ₹3,000–₹6,000 (or even lower). While this means millions of Indians can finally access effective treatment for obesity and diabetes, it also brings important risks related to poor manufacturing quality and dangerous, unsupervised self-medication.
The Burden of Obesity, Diabetes, and Heart Disease in India
India is facing a tsunami of metabolic and cardiovascular diseases, driven heavily by changing diets, sedentary urban lifestyles, and a high rate of obesity and its related complications, including diabetes and heart disease.
According to a comprehensive, nationwide study called the Indian Council of Medical Research–India Diabetes (ICMR-INDIAB) study, there are an estimated 101 million people suffering from diabetes in India, with another 136 million classified as prediabetic. That gives India the dubious distinction of second place amongst countries with the highest number of people with diabetes. Furthermore, over 50% of diabetes remain undiagnosed.
To further add to the risk: Indians are genetically more likely to develop coronary artery disease (blockages in the arteries of the heart) about a decade earlier than their European counterparts — and obesity makes this worse. A recent systematic review shows the prevalence of coronary artery disease among Indian adults is alarmingly high at 11%, with urban populations experiencing a 12% prevalence compared to 6% in rural areas. Coronary artery disease is the leading cause of death in India.
The Good News: Semaglutide Works Well in Selected Patients
Semaglutide — the generic name for Ozempic or Wegovy, is a GLP-1 receptor agonist that mimics a naturally occurring gut hormone that regulates your appetite and blood sugar, effectively tricking your body into feeling full faster and staying full longer.
Beyond driving significant weight loss, semaglutide is highly effective in treating type 2 diabetes and offers profound benefits for overall metabolic health. It is a game-changer for reducing cardiovascular disease, helping to prevent heart attacks, kidney failure, and strokes. Cardiologists utilize these medications to treat obesity when it occurs alongside hypertension, diabetes, high cholesterol, heart failure, and sleep apnea.
The Bad News: The Dangers of Generic Semaglutide in India
Until now, monthly treatments of branded GLP-1 drugs cost anywhere from ₹8,800 to ₹20,000, placing them out of reach for most Indians. With the patent expired, more than 40 Indian pharmaceutical companies are rushing to release over 50 generic brands simultaneously, and prices are expected to plummet to between ₹3,000 and ₹6,000 per month. However, this “magic-pill moment” comes with serious downsides:
- The Risks of Self-Medication: India has a widespread culture of over-the-counter drug purchases where self-medication is common. Semaglutide is a serious prescription medicine with a complex safety profile; it is a weekly injection that demands strict medical supervision, specific lifestyle changes, and nutritional compliance.
- Severe Side Effects: Unmonitored use of semaglutide can be highly dangerous. Semaglutide is not a supplement like protein powder. It is a prescription drug that can have severe side effects in some patients, especially those with a history of pancreatitis or a family history of certain types of thyroid or endocrine cancers. Side effects can range from nausea, vomiting, and rapid muscle loss to severe conditions like pancreatitis. A doctor’s supervision is required to take these medications safely and manage the side effects.
- Quality Control Concerns: Semaglutide is not a simple chemical pill. It is a complex biologic peptide produced using recombinant DNA technology. With more than 40 companies aggressively racing to launch, the pressure to cut corners is immense, raising valid concerns about whether these generic copies will be as safe and effective as the original. Importantly, these medicines need to be kept refrigerated, and if the cold chain is broken during transportation or storage, efficacy will be reduced.
Summary
The arrival of generic semaglutide in India offers a powerful, much-needed, and affordable tool to combat the country’s severe obesity, diabetes, and cardiovascular crises. However, the complex manufacturing requirements of these biologic drugs and the severe risks associated with unsupervised self-medication mean that patients must exercise extreme caution. To achieve safe and lasting results, these medications must only be used under the strict supervision of experienced physicians.
Reviewed for medical accuracy by Dr. Srikanth Sola. Last updated: April 7, 2026
References for detailed reading
- Anjana RM, et al. ICMR–INDIAB Collaborative Study Group. Prevalence of diabetes and prediabetes in 15 states of India: results from the ICMR-INDIAB population-based cross-sectional study. Lancet Diabetes Endocrinol. 2017 Aug;5(8):585-596. doi: 10.1016/S2213-8587(17)30174-2.
- Shannawaz M, et al. Prevalence of CVD Among Indian Adult Population: Systematic Review and Meta-Analysis. Int J Environ Res Public Health. 2025; 22(4):539.